Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians

doi:10.5306/wjco.v7.i1.27

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9823)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

1010

WORD

491

HTML

5656

Figures (1-2)

140

Tables (1-4)

159

Sum=7456

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1041

Download

1326

Sum=2367

Feb 10, 2016 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (60)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Feb 10, 2016; 7(1): 27-43
Published online Feb 10, 2016. doi: 10.5306/wjco.v7.i1.27

Table 4 Available and ongoing clinical results about drugs targeting mainly stroma in pancreatic adenocarcinoma

Combination	Target (s)	Setting	Clinical trial identifier¹	Expected end of accrual
Demcizumab	Cancer stem cells by DLL4 inhibition	Phase Ib, plus GEM +/- Nab-P	NCT01189929	Concluded. presented at ASCO 2014: Increase in ORR, cardiovascular toxicity
(Gracian 2014)	Cancer stem cells by DLL4 inhibition	Phase Ib, plus GEM +/- Nab-P	NCT01189929
Ruxolitinib (Hurwitz 2014)	Inflammation by JAK/STAT inhibition	Phase II, 2^nd line, plus CAPE	NCT01423604	Concluded. presented at ASCO 2014: Benefit in patients with elevated CRP
PEGPH20	HA by Pegylated-hyaluronidase	Phase II, 1^st line, plus GEM	NCT01453153	Concluded. presented at ASCO 2013: ORR 33%, especially in patients with high HA expression
(Hingorani 2013)S	HA by Pegylated-hyaluronidase	Phase II, 1^st line, plus GEM	NCT01453153
‘’	‘’	Phase II, plus GEM + Nab-P	NCT01839487	July 16

CAPE: Capecitabine; CRP: C-reactive protein; GEM: Gemcitabine; HA: Hyaluronic acid; ORR: Objective response rate; DLL4: Delta like ligand 4; ASCO: American society of clinical oncology; JAK/STAT: Janus kinase/signal transducer and activator of transcription; Nab-P: Nab-paclitaxel.

¹Data Available from: URL: http// http://www.clinicaltrials.gov (last access 2015 May 24).

Citation: Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, Satolli MA. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol 2016; 7(1): 27-43
URL: https://www.wjgnet.com/2218-4333/full/v7/i1/27.htm
DOI: https://dx.doi.org/10.5306/wjco.v7.i1.27